Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Anton V. Bieliauskas"'
Publikováno v:
ACS Medicinal Chemistry Letters. 8:281-286
Histone deacetylase (HDAC) proteins are epigenetic regulators that deacetylate protein substrates, leading to subsequent changes in cell function. HDAC proteins are implicated in cancers, and several HDAC inhibitors have been approved by the FDA as a
Publikováno v:
Archiv der Pharmazie. 349:373-382
Histone deacetylase (HDAC) proteins have emerged as targets for anti-cancer therapeutics, with several inhibitors used in the clinic, including suberoylanilide hydroxamic acid (SAHA, vorinostat). Because SAHA and many other inhibitors target all or m
Publikováno v:
ChemInform. 39
Histone deacetylase (HDAC) proteins are transcription regulators linked to cancer. As a result, multiple small molecule HDAC inhibitors are in various phases of clinical trials as anti-cancer drugs. The majority of HDAC inhibitors non-selectively inf
Histone deacetylase (HDAC) proteins are transcription regulators linked to cancer. As a result, multiple small molecule HDAC inhibitors are in various phases of clinical trials as anti-cancer drugs. The majority of HDAC inhibitors non-selectively inf
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::913dea9d216a5a2ee3492f15ca61e43b
https://europepmc.org/articles/PMC2593472/
https://europepmc.org/articles/PMC2593472/
Inhibitors of histone deacetylase (HDAC) proteins such as suberoylanilide hydroxamic acid (SAHA) have emerged as effective therapeutic anti-cancer agents. To better understand the structural requirements of HDAC inhibitors, a small molecule library w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91bd1e9ea88fac2e79425a3ba49ce71b
https://europepmc.org/articles/PMC1896371/
https://europepmc.org/articles/PMC1896371/
Publikováno v:
Chemical Society Reviews; Jun2008, Vol. 37 Issue 7, p1402-1413, 12p